Diagnosis and Treatment of Osteoporosis: A Case-Based Approach is a practical guide that will be useful to a wide range of practicing and in-training clinicians, including physicians, nurse practitioners and physician assistants. With its clinical case and scenario-based approach, readers can quickly decide which clinical problem to address such as the management of osteoporosis of a particular clinical problem (Atypical femoral shaft fractures, Glucocorticoids and bone health, etc.). Each chapter is self-contained with a list of objectives at the beginning and a presentation of clinical cases that encourages self-learning to non-specialized clinical staff. This book is easily accessible to non-specialists, allowing any healthcare provider to learn how to diagnose and manage osteoporosis in the context of their practice.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Section 1: The diagnosis of osteoporosis - p. iii 7. Chapter 1. Clinical diagnosis: Fragility hip fracture - p. 3 8. Clinical diagnosis: Fragility fracture long bones - p. 15 9. Clinical diagnosis: Acute vertebral fragility fracture - p. 25 10. Opportunistic/morphometric diagnosis—Silent vertebral fractures - p. 39 11. Densitometric diagnosis: DXA scans - p. 51 12. Osteopenia: Individualizing treatment—Part I - p. 71 13. Osteopenia: Individualizing treatment—Part II - p. 81 14. Osteopenia: Individualizing treatment—Part III - p. 89 15. Osteopenia: Individualizing treatment—Part IV - p. 97 16. Screening for osteoporosis - p. 107 17. Section 2: Pharmacological treatment - p. 123 18. Oral bisphosphonates—Initiating and maintaining treatment - p. 127 19. Chapter 12. Oral bisphosphonates—Drug holidays and discontinuing therapy - p. 137 20. Chapter 13. Oral bisphosphonates—Long term: 13 years - p. 147 21. Oral bisphosphonates—Lack of response - p. 157 22. Zoledronic acid—Annual infusions - p. 165 23. Receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor—Denosumab - p. 175 24. Sclerostin inhibitor (SERM): Raloxifene - p. 185 25. Sclerostin inhibitor (SERM): Romosozumab - p. 193 26. Chapter 19. Parathyroid hormone analogs - p. 201 27. Atypical femoral fractures - p. 221 28. Osteonecrosis of the jaw - p. 233 29. Chapter 22. Drug holidays - p. 245 30. Section 3: Select populations - p. 249 31. Osteoporosis in men - p. 253 32. Premenopausal women with low bone mass - p. 267 33. Osteoporosis in older adults - p. 279 34. Chapter 26. Low bone mass and osteoporosis in young adults - p. 289 35. Iatrogenic osteoporosis - p. 297 36. Primary hyperparathyroidism - p. 305 37. Section 4: Diet, calcium, magnesium, vitamin D, and lifestyle changes - p. 319 38. Calcium and vitamin D disorders. Part I: Mild hypocalcemia - p. 323 39. Chapter 30. Calcium and vitamin D disorders: Part II: Hypovitaminosis D - p. 331 40. Calcium and vitamin D disorders: Part III: From hypovitaminosis to hypervitaminosis D - p. 339 41. Magnesium - p. 347 42. Physical exercise and bone health - p. 353 43. Falls—Part I—Endogenous causes - p. 361 44. Falls—Part II—Environmental hazards - p. 369 45. Index - p. 379
Diagnosis and Treatment of Osteoporosis: A Case-Based Approach is a practical guide that will be useful to a wide range of practicing and in-training clinicians, including physicians, nurse practitioners and physician assistants. With its clinical case and scenario-based approach, readers can quickly decide which clinical problem to address such as the management of osteoporosis of a particular clinical problem (Atypical femoral shaft fractures, Glucocorticoids and bone health, etc.). Each chapter is self-contained with a list of objectives at the beginning and a presentation of clinical cases that encourages self-learning to non-specialized clinical staff. This book is easily accessible to non-specialists, allowing any healthcare provider to learn how to diagnose and manage osteoporosis in the context of their practice.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Section 1: The diagnosis of osteoporosis - p. iii 7. Chapter 1. Clinical diagnosis: Fragility hip fracture - p. 3 8. Clinical diagnosis: Fragility fracture long bones - p. 15 9. Clinical diagnosis: Acute vertebral fragility fracture - p. 25 10. Opportunistic/morphometric diagnosis—Silent vertebral fractures - p. 39 11. Densitometric diagnosis: DXA scans - p. 51 12. Osteopenia: Individualizing treatment—Part I - p. 71 13. Osteopenia: Individualizing treatment—Part II - p. 81 14. Osteopenia: Individualizing treatment—Part III - p. 89 15. Osteopenia: Individualizing treatment—Part IV - p. 97 16. Screening for osteoporosis - p. 107 17. Section 2: Pharmacological treatment - p. 123 18. Oral bisphosphonates—Initiating and maintaining treatment - p. 127 19. Chapter 12. Oral bisphosphonates—Drug holidays and discontinuing therapy - p. 137 20. Chapter 13. Oral bisphosphonates—Long term: 13 years - p. 147 21. Oral bisphosphonates—Lack of response - p. 157 22. Zoledronic acid—Annual infusions - p. 165 23. Receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor—Denosumab - p. 175 24. Sclerostin inhibitor (SERM): Raloxifene - p. 185 25. Sclerostin inhibitor (SERM): Romosozumab - p. 193 26. Chapter 19. Parathyroid hormone analogs - p. 201 27. Atypical femoral fractures - p. 221 28. Osteonecrosis of the jaw - p. 233 29. Chapter 22. Drug holidays - p. 245 30. Section 3: Select populations - p. 249 31. Osteoporosis in men - p. 253 32. Premenopausal women with low bone mass - p. 267 33. Osteoporosis in older adults - p. 279 34. Chapter 26. Low bone mass and osteoporosis in young adults - p. 289 35. Iatrogenic osteoporosis - p. 297 36. Primary hyperparathyroidism - p. 305 37. Section 4: Diet, calcium, magnesium, vitamin D, and lifestyle changes - p. 319 38. Calcium and vitamin D disorders. Part I: Mild hypocalcemia - p. 323 39. Chapter 30. Calcium and vitamin D disorders: Part II: Hypovitaminosis D - p. 331 40. Calcium and vitamin D disorders: Part III: From hypovitaminosis to hypervitaminosis D - p. 339 41. Magnesium - p. 347 42. Physical exercise and bone health - p. 353 43. Falls—Part I—Endogenous causes - p. 361 44. Falls—Part II—Environmental hazards - p. 369 45. Index - p. 379
